| Old Articles: <Older 4991-5000 Newer> |
|---|
 |
The Motley Fool
July 24, 2008
Brian Lawler |
Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last.   |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool
July 23, 2008
Brian Orelli |
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. |
The Motley Fool
July 22, 2008
Brian Orelli |
The Growth Doctor Is In Dr. Reddy's grows the top line, but it still has some work to do. |
The Motley Fool
July 22, 2008
Brian Orelli |
Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck. |
The Motley Fool
July 22, 2008
Brian Orelli |
Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around. |
The Motley Fool
July 22, 2008
Brian Lawler |
Anxiously Awaiting Exelixis Pivotal clinical trial results for a top drug are finally within sight. Investors, take note. |
Scientific American
August 2008
Gary Stix |
Can fMRI Really Tell if You're Lying? Will brain scans ever be able to tell if you're really being deceptive? |
Scientific American
August 2008
Emily Harrison |
Unlikely Victims of Banning CFCs--Asthma Sufferers New CFC-free inhalers cost three times more than their CFC counterparts. |
| <Older 4991-5000 Newer> Return to current articles. |
